Research-Use-Only Compliance Checklist for Canadian Peptide Content and Supplier Pages

Quick answer: what RUO compliance should look like#

A research-use-only compliance checklist should answer one practical question: can a reader understand the material and its documentation without being pushed toward human use? If the answer is no, the page is not clean enough for a Canadian research peptide funnel.

For Northern Compound, a compliant RUO page has five visible traits:

1. it names the peptide or research material accurately;
2. it points the reader toward current batch documentation, especially a lot-matched certificate of analysis;
3. it explains the non-clinical research model or endpoint without turning it into a consumer benefit;
4. it avoids administration, dosing, treatment, performance, cosmetic, and personal-use claims; and
5. it routes qualified readers through auditable product pages rather than hype.

That standard applies to broad supplier guides, compound-specific pages, category pages, outreach copy, and product links. A reader can inspect BPC-157, Semaglutide, GHK-Cu, or Selank only after the research question and documentation requirements are clear. When a recovery page mentions pain-like behaviour, mobility, guarding, allodynia, or sensitisation, use the nociception recovery peptide guide as the claims boundary: behaviour belongs in model interpretation, not in personal-use promises. A ProductLink is a documentation checkpoint, not a human-use recommendation.

This page is a linkable asset for Canadian researchers, editorial teams, and supplier reviewers who need a practical claims audit. It is research-use-only. It is not medical advice, legal advice, dosing guidance, injection guidance, cosmetic guidance, veterinary advice, disease guidance, or a recommendation for personal use.

When the claim review is tied to a real purchase or lot, preserve the result in the research peptide batch documentation template. When the review is tied to one live supplier page, use the research peptide product page claims audit to score the headline, imagery, FAQ, CTA, COA path, storage language, and support route before the page is treated as a clean research destination. A clean RUO page, a lot-matched COA, and a receipt/storage record should point to the same research-material file rather than living as disconnected notes.

Why RUO language matters more in peptide content#

Peptide content is unusually easy to overstate. The same compound can appear in basic biology papers, animal models, unauthorized consumer marketing, cosmetic discussions, bodybuilding forums, and legitimate drug-development literature. If a supplier page borrows language from the loudest market instead of the most disciplined evidence layer, the page can become misleading very quickly.

Health Canada has repeatedly warned consumers about unauthorized injectable peptide products sold online and promoted for outcomes such as anti-aging, weight loss, bodybuilding, athletic performance, and injury recovery. That warning context matters for Canadian editorial work. It means a peptide page should not use RUO language as a decorative footer while the rest of the page implies personal benefit.

The same principle shows up in broader advertising rules. The Competition Bureau's deceptive-marketing guidance focuses on the general impression created by a representation, not only the literal sentence a company prefers to isolate. In practice, a page that says "research-use-only" in one line but surrounds it with human transformation copy, testimonials, dose language, or before-and-after imagery still creates the wrong general impression.

RUO discipline is therefore not just a regulatory posture. It improves content quality. It forces the writer to separate what is known, what is model-specific, what is analytically documented, what is speculative, and what should not be said.

The Northern Compound RUO claims ladder#

Use this ladder before writing or approving any peptide page.

The key move is to write from the lab record outward. Start with identity, lot, method, storage, and endpoint. Do not start with desired human outcomes and then add a disclaimer at the bottom. When a page has to mention reconstitution, keep it as documentation language: link to the peptide reconstitution search-intent map or the documentation handoff checklist, and avoid phrasing that sounds like dosing, injection training, compounding, or personal-use preparation.

The page-level RUO compliance checklist#

Use this checklist for any Canadian research peptide article, category page, product page, supplier review, or outreach asset.

1. Headline and metadata#

• Does the title describe research context rather than personal benefit?
• Does the meta description avoid treatment, cure, recovery, weight-loss, anti-aging, bodybuilding, sexual-performance, anxiety, sleep, tanning, or cosmetic-result promises?
• Does the slug signal research or documentation rather than human use?
• Does the page avoid words like "protocol," "cycle," "dose," "stack," or "results" when those words would imply personal use?
• If a disease or condition term appears, is it clearly tied to literature context rather than a product promise?

Good example: "Where to Buy Research Peptides in Canada: A COA-First Supplier Checklist."

Weak example: "Best Peptide Stack for Injury Recovery and Fat Loss."

The weak version collapses multiple claims into a consumer promise. The better version frames the page as supplier evaluation and documentation review.

2. Opening disclosure#

The first screen should make the editorial boundary obvious. A reader should not need to reach the footer before understanding that the content is RUO-only.

A strong opening disclosure says:

This article discusses research-use-only peptide materials, supplier documentation, and non-clinical endpoint design. It does not provide medical advice, dosing information, administration instructions, treatment recommendations, cosmetic guidance, athletic advice, or personal-use recommendations.

That language is intentionally plain. It does not hide the boundary in legal fog. It tells the reader what the page is and what it is not.

3. Product identity and naming#

Every product reference should be specific enough to audit. Generic phrases like "healing peptides," "fat-loss peptides," "brain peptides," or "skin peptides" may work as category shorthand, but they cannot replace exact identity.

For each material, check:

• exact compound name;
• alternate names only when needed for clarity;
• salt, analogue, complex, or blend status when relevant;
• fill amount or vial size if a product page is being reviewed;
• whether the page makes clear that blends need separate identity logic;
• whether similar names could be confused.

A page about CJC-1295 with DAC should not blur into CJC-1295 without DAC. A page about GHK-Cu should not quietly shift into cosmetic copper-peptide claims. A page about Tirzepatide should not treat every incretin compound as interchangeable. A page about a fixed BPC-157/TB-500 blend should not borrow claims from either component without explaining the combined material; use the blend supplier checklist when ratio, dual identity, and batch language need their own audit trail.

4. COA and batch documentation#

The strongest RUO copy points readers toward verification rather than trust. A supplier page should make it easy to inspect the current material.

Minimum documentation prompts:

• Does the COA match the current lot or batch?
• Does the COA identify the compound by name?
• Does it include HPLC, UPLC, mass spectrometry, or another relevant identity/purity method?
• Are test date, batch number, fill amount, and responsible laboratory or issuer clear?
• Is the storage condition visible and compatible with the material?
• Is there a path to request batch-specific documentation if not exposed on-page?
• Does the product page avoid substituting generic purity claims for actual records?

A COA is not automatically perfect. It can be stale, generic, mismatched, incomplete, or method-poor. The useful editorial standard is not "has COA." It is "can the reader connect the named product, current lot, test method, and storage expectations into a defensible research record?"

5. Endpoint framing#

RUO pages should use endpoint language instead of outcome language.

For recovery research, that means cell migration, inflammatory markers, angiogenesis markers, collagen organization, tissue-remodelling assays, or repair-model endpoints. It does not mean promising that a person will recover from injury.

For incretin research, that means receptor activity, glucose-handling models, gastric-emptying endpoints, satiety-signal biology, body-weight endpoints in controlled animal models, or comparator design. It does not mean telling a reader how to lose weight.

For cognitive research, that means neurotrophic markers, stress-axis measures, behavioural assays in preclinical models, synaptic plasticity endpoints, or sleep-architecture measures. It does not mean promising focus, anxiety relief, mood improvement, or better sleep.

For skin research, that means fibroblast activity, matrix markers, pigmentation pathways, barrier models, antimicrobial peptide signalling, or inflammatory cytokines. It does not mean recommending topical use, tanning, brightening, anti-wrinkle routines, or cosmetic outcomes.

6. CTA and ProductLink language#

A compliant CTA should send the reader to documentation, not to use. ProductLinks should be framed as inspection routes.

Use:

• "Inspect the current product page and batch documentation."
• "Verify the COA before adding the material to a research plan."
• "Use the listing as a documentation checkpoint, not a clinical recommendation."
• "Compare the identity, purity method, storage, and endpoint fit."

Avoid:

• "Start with this peptide."
• "Use this for recovery."
• "Run this stack."
• "Best dose."
• "Before and after."
• "Transform your body/skin/focus."

Northern Compound uses ProductLink components so LynxLabs attribution is preserved with UTM parameters. That technical detail matters because it lets editorial pages route qualified traffic without hardcoding raw product URLs or breaking analytics.

The prohibited-claims audit table#

This table is deliberately blunt. Most compliance failures happen because marketing copy tries to be exciting. The safer move is to be more useful: name the research model, name the endpoint, and name the documentation gap.

Supplier-page scorecard#

Use the following 20-point scorecard when reviewing a Canadian peptide supplier page. A page does not need to be perfect to be worth inspecting, but low scores should slow the click.

Interpretation:

• 17-20: strong documentation-first page;
• 13-16: usable with manual verification;
• 9-12: weak page that needs more documentation or claim cleanup;
• 0-8: avoid routing high-intent readers until fixed.

General-impression risk matrix#

A useful RUO audit has to look past isolated sentences. The Competition Bureau's general-impression concept is helpful because a page can be literally cautious in one line and still create a risky overall impression through layout, image choice, CTA order, FAQ wording, and product-card framing. For peptide content, review the whole decision path before approving the page.

The audit question is not "can we defend this one sentence?" It is "what would a reasonable reader think the page is encouraging them to do?" If the answer sounds like human use, the page needs revision even if it contains an RUO disclaimer somewhere else.

One-screen RUO audit worksheet#

Use this worksheet when reviewing a draft article, supplier page, newsletter paragraph, product-card caption, outreach pitch, or social snippet. It is designed to be copied into an editorial ticket or supplier-review note.

This worksheet makes the checklist more linkable because it gives outside readers a reusable artifact, not just advice. A lab operator can paste it into procurement notes. An editor can paste it into a content review. A supplier reviewer can paste it into a page audit before deciding whether to request a current COA.

Copy-paste RUO release gate#

Use this release gate when a peptide page is one approval step away from publication, supplier routing, newsletter inclusion, or outreach. The point is not to create a legal opinion. The point is to make the claim boundary visible before the asset reaches a reader.

RUO RELEASE GATE
Page or asset:
Reviewer:
Date:

1. Intended use frame
[ ] The asset is clearly about research-use-only materials, documentation, non-clinical models, supplier review, or endpoint design.
[ ] It does not address a patient, consumer, athlete, cosmetic user, or self-experimenter as the intended user.
[ ] The opening screen says what the page is not: no medical advice, dosing, administration, treatment, cosmetic guidance, athletic advice, or personal-use recommendation.

2. General impression
[ ] Title, meta description, hero image, opening copy, first CTA, FAQ, and ProductLinks create a documentation-first impression.
[ ] No single disclaimer is being used to excuse benefit-led body copy.
[ ] Images do not imply injection, transformation, recovery, tanning, cosmetic improvement, gym performance, or self-use.

3. Prohibited language scan
[ ] No dosing, route, injection, protocol-for-use, cycle, transformation, before-and-after, testimonial, cure, treatment, or disease-use language appears as advice.
[ ] Weight-management, recovery, cognitive, skin, anti-aging, and hormone terms are tied to research endpoints, not personal outcomes.
[ ] Any risky phrase appears only as a claim-to-avoid example or regulatory/literature context.

4. Documentation path
[ ] The page tells the reader what to verify: exact identity, lot or batch, COA, analytical method, fill amount, storage condition, and support route.
[ ] ProductLinks are introduced as documentation checkpoints and preserve attribution.
[ ] No raw Lynx product URLs are present in MDX copy.

5. Decision
[ ] Approve.
[ ] Clarify before publication.
[ ] Rewrite before publication.
[ ] Remove commercial route.
[ ] Reject.

Reason:
Next reviewer:

This gate is intentionally short enough to live in a CMS ticket, GitHub PR, supplier-review note, or content QA checklist. If a reviewer cannot tick the first two sections without caveats, the page is not ready for traffic. If the problem is only a vague sentence or ambiguous anchor, rewrite it. If the problem is the whole angle, stop routing readers to the page until the search intent is reframed.

Product-page claim examples by category#

The same RUO rule fails in different ways by category. A claim audit is stronger when the reviewer knows what the risky version usually sounds like.

Use the table as a triage tool. If the risky phrase appears in a title, meta description, CTA, ProductLink sentence, FAQ question, or image alt text, fix it before deeper scientific editing. Short surfaces carry disproportionate risk because they are what search results, cards, and skim readers see first.

Source-citation discipline for RUO claims#

A compliance-safe article can still overreach if it uses citations loosely. The audit should ask what each source is being asked to prove.

The safest sentence pattern is: “Source X supports principle Y, but it does not establish Z.” That pattern prevents citation laundering. It is especially useful on pages where a commercial route appears near scientific literature. The literature may explain why a compound is interesting; it does not make a live product page clinically appropriate, personally usable, or exempt from documentation review.

First-screen commercial route audit#

Most risky peptide pages fail before the reader reaches the detailed evidence section. The first screen usually carries the strongest general impression: title, hero image, first disclosure, first product route, first CTA, and any visible trust badges. If that surface feels like consumer conversion, the rest of the article has to work uphill.

Use this pass before approving any page that contains ProductLinks, supplier comparisons, category tiles, or buyer-intent language.

This audit is especially important on high-intent pages such as “where to buy” articles. Those pages can still convert, but the conversion event should be a qualified documentation inspection, not a nudge toward personal use. A reader who opens a Semaglutide, BPC-157, GHK-Cu, or Selank route should already know what evidence they are looking for and what claims should make them stop.

Pass/fail language for the audit note#

Copy one of these notes into an editorial ticket or supplier-review record.

Pass: First screen reviewed. Title, image, opening disclosure, first ProductLink, and CTA frame the page as research-use-only documentation review. No dosing, injection, treatment, cosmetic-result, personal weight-loss, athletic-performance, anxiety/sleep, cycle, protocol, before-and-after, or testimonial claims appear before the evidence section.

Clarify: First screen is mostly RUO-safe, but [surface] needs revision because [specific phrase/image/CTA] could create a personal-use impression. Page should not be published or routed until the surface is rewritten and rechecked against the claims ladder.

Reject/rewrite: First screen creates a consumer-use general impression. The page opens with [benefit/personal-use/commercial urgency], and the RUO disclaimer does not control the surrounding claim. Rewrite from identity, endpoint, COA, storage, and supplier-documentation evidence before adding ProductLinks.

Category-specific claims boundary map#

The same forbidden claim can appear in different clothing across Northern Compound categories. A recovery page may overclaim injury repair. A skin page may overclaim cosmetic use. A cognitive page may overclaim mood, focus, sleep, or anxiety. A weight-management page may overclaim body-weight outcomes. The audit should therefore translate the general rule into category-specific checks.

This map prevents a subtle problem: a writer may avoid the obvious word “treat” but still create the same consumer impression with category-specific synonyms. “Supports recovery,” “skin benefits,” “focus peptide,” “GH optimization,” and “weight-management stack” can all become unsafe if they point toward personal outcomes instead of research endpoints.

ProductLink sentence-pattern library#

ProductLinks are where editorial quality and conversion quality meet. A clean link should preserve attribution, help a qualified reader inspect a current listing, and keep the surrounding sentence inside a research documentation frame. The safest pattern is compound + endpoint lane + evidence condition + no personal-use implication.

Use these sentence patterns when an article needs a commercial route without turning the route into advice.

Avoid ProductLink sentences that begin with “use this for,” “best for,” “start with,” “stack with,” or “results.” Those phrases are efficient for consumer marketing, which is exactly why they are wrong for RUO pages. Northern Compound can still route traffic to LynxLabs, but the traffic should arrive with the right mental model: inspect the material, verify the lot, document the record, and keep the research boundary intact.

ProductLink review note#

Copy this into the article review when a page contains commercial routes:

ProductLinks reviewed. Each link is relevant to the stated research model, introduced as a documentation checkpoint, and surrounded by identity, COA, storage, endpoint, or claim-boundary language. No ProductLink appears as dosing, administration, treatment, cosmetic, weight-loss, performance, anxiety/sleep, cycle, or personal-use advice. No raw product URLs are used in MDX body copy.

When to remove a commercial route entirely#

Sometimes the right compliance move is not to rewrite the sentence. It is to remove the link. A ProductLink should be omitted when the page cannot explain why that exact material belongs in the research question, when the live product status is uncertain, when the surrounding section is mostly about claims to avoid, or when the link would make a cautionary paragraph feel like a buying suggestion.

Remove or defer the route when:

• the paragraph discusses unauthorized-use warnings, enforcement, seizures, or consumer risk;
• the only available anchor text would be a disease, injury, cosmetic, weight-loss, performance, or mental-health phrase;
• the compound is mentioned only as a bad example or market-overclaim example;
• the article has not yet explained the endpoint lane or documentation minimum;
• the product slug is known to be unavailable or cannot be verified without falling back safely;
• the link would sit beside urgent commercial language such as “order,” “try,” “start,” “cycle,” or “protocol.”

Removing a link is not lost conversion if the link would attract the wrong click. The better path is to send readers to a broader supplier guide, COA checklist, or category matrix first, then introduce ProductLinks only when the reader knows what they are auditing.

Outreach and partner-use version#

If this checklist is shared with a lab, supplier reviewer, newsletter editor, or Canadian biotech operator, keep the pitch narrow. The linkable asset is not a claim that Northern Compound can certify a supplier. It is a reusable method for reducing claim drift on research-material pages.

Suggested short description:

Northern Compound maintains a practical RUO claims-audit checklist for Canadian peptide content. It covers first-screen general impression, prohibited language, ProductLink framing, COA and batch-documentation prompts, category-specific claim drift, and copy-paste reviewer notes. It is designed for editorial review and supplier-page audits, not medical advice or personal-use guidance.

Suggested link anchors:

• research-use-only compliance checklist;
• RUO claims audit worksheet;
• Canadian peptide content compliance checklist;
• peptide supplier page claims audit;
• COA and RUO documentation checklist.

Do not pitch the asset as a product endorsement, legal opinion, or evidence that any material is safe for human use. The strongest outreach angle is narrower: better claim discipline helps readers, suppliers, and editors keep research documentation separate from consumer marketing.

Regulatory-source map for Canadian RUO content#

This article is not legal advice, but source discipline matters. The safest editorial posture is to cite regulatory and standards material for the principle it actually supports, then keep peptide-specific interpretation conservative.

The mistake to avoid is citation laundering. Do not cite a regulatory page about unauthorized products and then imply that one supplier route is endorsed. Do not cite quality guidance and imply the product is GMP unless the supplier can document that claim. References should narrow the claim, not inflate it.

Editorial workflow for new Northern Compound posts#

A Northern Compound peptide article should pass this workflow before publishing.

1. Define the public category: weight-management, recovery, growth-hormone, anti-aging, cognitive, or skin.
2. Define the content type by folder: buyer-intent, comparison, deep-dive, quick-answer, news-trend, or stack-guide. Do not create new pillar posts for routine assets.
3. Choose a target keyword that can be answered without human-use advice.
4. Write the answer-first section with an RUO boundary in the first screen.
5. Add tables, checklists, FAQs, and internal links that make the page useful as a reference.
6. Use ProductLink for Lynx routes and avoid raw product URLs.
7. Cross-check product slugs against live product availability when adding new links.
8. Avoid inline bottom CTAs or duplicate disclaimers because the article template already renders global trust and CTA blocks.
9. Verify internal links, external references, image URLs, and build output.
10. Re-read the page as if a regulator, researcher, supplier, and skeptical reader each opened it cold.

The final review question is simple: if someone stripped the footer disclaimer from the page, would the body copy still clearly read as research-use-only? If not, rewrite the body copy.

Copy blocks you can reuse#

Safe opening disclosure#

This article discusses research-use-only materials, non-clinical research models, supplier documentation, and endpoint design. It does not provide medical advice, dosing information, administration instructions, treatment recommendations, cosmetic guidance, athletic advice, or personal-use recommendations.

Safe ProductLink lead-in#

Use the product page as a documentation checkpoint. Verify the current lot, COA, identity method, storage language, and endpoint fit before treating the listing as credible for a research plan.

Safe supplier-review line#

A credible supplier page should make the material easier to audit, not easier to misuse.

Safe FAQ refusal#

No. Northern Compound does not provide dosing, reconstitution-for-use, route, cycle, injection, or personal-use guidance for research peptides.

Safe commercial disclosure#

Northern Compound may use attribution links to LynxLabs product pages. Those links support measurement and supplier review, but they do not change the research-use-only boundary or create a personal-use recommendation.

Red flags that should trigger a rewrite#

• The headline promises a human result.
• The hero image looks like personal use, injection, transformation, gym marketing, or cosmetic before-and-after content.
• The first CTA appears before the page explains documentation checks.
• The article ranks products by outcome strength instead of endpoint fit.
• The FAQ answers dosing, route, cycle, reconstitution, or personal-use questions.
• A disease term appears in a buying sentence.
• A cosmetic term appears in a recommendation sentence.
• A product link is used as evidence instead of as a route to inspect documentation.
• The page cites a clinical or preclinical paper but skips model limitations.
• The page says "not for human consumption" while the rest of the copy clearly targets human consumption.

The last point is common and worth saying plainly: disclaimers do not fix contradictory copy. If the body of the page behaves like consumer marketing, a footer label will not make it rigorous.

Internal-link map for this checklist#

This checklist should support high-intent supplier pages and category guides. Use it as the compliance reference when a page needs to explain why Northern Compound avoids aggressive claims.

Recommended internal anchors:

This is a linkable asset because it is useful outside a single compound. It can earn links from supplier-review pages, lab documentation posts, compliance roundups, Canadian biotech newsletters, harm-reduction explainers, and research procurement guides without drifting into medical advice.

How to audit an existing article in 10 minutes#

Use this fast pass when an older post needs a refresh.

1. Search the article for: dose, dosing, inject, injection, protocol, cycle, heal, cure, treat, recover, fat loss, anti-aging, optimize, anxiety, sleep, tanning, wrinkle, before and after.
2. For each hit, decide whether the word is necessary literature context or accidental consumer framing.
3. Replace outcome claims with endpoint claims.
4. Move RUO disclosure closer to the top if the page waits too long.
5. Add one link to a relevant compliance or COA checklist when the page discusses buying or supplier trust.
6. Confirm all Lynx routes use ProductLink rather than raw URLs.
7. Confirm the product slug is live or safely falls back.
8. Check that references support the exact claim being made.
9. Remove customer stories, testimonials, or personal-use anecdotes.
10. Rebuild and inspect the rendered page.

The goal is not to make every page timid. The goal is to make every page precise.

Before-and-after rewrite examples#

The fastest way to improve a risky peptide page is not to delete every useful concept. It is to move from outcome language to documentation and endpoint language. These examples show the difference.

This is the editorial habit to build: whenever a sentence sounds like a benefit, ask what measurement would actually support it. If the answer is a clinical endpoint, personal story, or consumer transformation, the sentence probably does not belong in RUO supplier content. If the answer is a non-clinical assay, analytical document, or model-specific endpoint, the sentence can usually be rewritten safely.

Image, testimonial, and social-proof rules#

RUO compliance is not only text. Images and social proof can create the same general impression as explicit claims.

Avoid hero images or product-page visuals that show:

• injections, syringes, or self-administration scenes;
• gym transformation imagery;
• before-and-after skin photos;
• beach, tanning, or cosmetic-result cues for melanocortin materials;
• injury, therapy, recovery, or rehab scenes attached to recovery peptides;
• bathroom-counter or lifestyle-use settings;
• customer screenshots or testimonial cards.

Use visuals that reinforce the research frame:

• lab benches, analytical instruments, notebooks, labels, or documentation;
• neutral product photography without route-of-use implication;
• charts, comparison tables, checklists, and process diagrams;
• document-review imagery for COA-first articles.

Testimonials are a separate problem. A customer story about feeling better, recovering faster, losing weight, sleeping better, tanning, or improving appearance is not appropriate evidence for RUO peptide materials. It is also not useful research documentation. If a page needs trust, use batch documentation, transparent methods, source citations, storage handling, and claim restraint instead of anecdotes.

Metadata and schema checks#

A page can have conservative body copy and still create problems in metadata. Before publishing, check the hidden and semi-hidden surfaces:

• title tag;
• meta description;
• Open Graph title and description;
• image alt text;
• FAQ answers;
• related-post labels;
• product-card captions;
• breadcrumbs;
• internal anchor text;
• sitemap/newsletter excerpts;
• ad copy or social snippets generated from the page.

The most common metadata failure is outcome compression. A careful article may spend 3,000 words explaining endpoint boundaries, then the meta description says "best peptides for fat loss, recovery, and anti-aging." That short snippet can become the page's most visible claim in search results and link previews.

For Northern Compound, metadata should usually include one of these stabilizers: research, research-use-only, supplier checklist, COA, documentation, non-clinical, endpoint, Canadian sourcing, or claims audit. Those words are not magic, but they pull the page back toward the intended use case.

ProductLink QA checklist#

ProductLinks are useful because they preserve LynxLabs attribution and keep URLs maintainable. They still need editorial QA.

Before publishing a page with ProductLinks, check:

1. Is the slug live or safely handled by the ProductLink component?
2. Is the linked material actually relevant to the section?
3. Does the surrounding sentence frame the link as inspection or documentation, not use?
4. Does the rendered URL include utm_source=northerncompound, utm_medium=blog, and a campaign value?
5. Does a product-specific link include utm_term so attribution remains useful?
6. Would the sentence still be compliant if the reader only read the linked phrase and CTA?
7. Does the page avoid raw lynxlabs.is/products URLs that bypass component safeguards?

A clean ProductLink sentence looks like this: For GLP-1 receptor-focused research, inspect the current <ProductLink slug="semaglutide">Semaglutide</ProductLink> listing and lot documentation before comparing broader incretin tools. The sentence does three jobs: it names the model, routes to the product page, and keeps verification ahead of purchase intent.

Outreach positioning for this asset#

This checklist is linkable because it is not just another peptide article. It is a reusable audit tool for a recurring problem: research-material pages often say RUO while the surrounding copy behaves like consumer marketing.

The best outreach angles are:

• lab documentation: how to keep COA, lot, and storage records tied to supplier pages;
• biotech marketing quality: how to avoid overclaiming in product copy;
• Canadian health-product advertising awareness: how general impression can matter;
• research procurement: how to compare supplier pages without relying on hype;
• editorial standards: how to write peptide content without dosing, treatment, or personal-use drift.

The outreach angle should not be "link to our peptide store." That would weaken the asset. The angle is that better claims discipline protects researchers, readers, suppliers, and the editorial funnel. A reader who understands compliance boundaries is more qualified than a reader attracted by promises Northern Compound should never make.

Maintenance cadence#

Revisit this checklist whenever one of these things changes:

• Health Canada publishes a new warning about unauthorized peptide or injectable products;
• Competition Bureau guidance on deceptive marketing changes;
• Northern Compound adds new ProductLink behavior or analytics fields;
• LynxLabs product availability changes materially;
• a new article type creates a new CTA surface;
• older posts are refreshed and need a standard claims-audit link;
• outreach targets ask for a shorter downloadable checklist or scorecard version.

The page should remain practical. If it turns into legal commentary, it will be less useful. If it becomes too generic, it will stop catching real peptide-content failures. The sweet spot is concrete: exact phrases, exact red flags, exact documentation checks, and a clear RUO boundary.

FAQ#

References and useful source material#

• Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm you.
• Health Canada. Unauthorized injectable drug products sold online by Canlab Research may pose serious health risks.
• Competition Bureau Canada. Misleading representations and deceptive marketing practices.
• Competition Bureau Canada. The general impression test.
• Health Canada and Competition Bureau Canada. Memorandum of Understanding between the Competition Bureau and Health Canada.
• U.S. Food and Drug Administration. Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only.
• ICH. Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.